These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 2099963

  • 1. Effects of defibrotide after oral and parenteral administration in patients with peripheral obliterative arterial disease (POAD).
    Craveri A, Tornaghi G, Ranieri R, Stanzani M, Landi G, Paganardi L, Passaretti B, Gallo E.
    Int Angiol; 1990; 9(4):274-7. PubMed ID: 2099963
    [Abstract] [Full Text] [Related]

  • 2. Effects of defibrotide on physical performance and hemorheologic picture in patients with peripheral arteriopathy.
    Marrapodi E, Leanza D, Giordano S, Nazzari M, Corsi C.
    Clin Trials Metaanal; 1994 Apr; 29(1):21-30. PubMed ID: 10150182
    [Abstract] [Full Text] [Related]

  • 3. A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease.
    Strano A, Fareed J, Sabbá C, Albano O, Allegra C, Carlizza A, Binaghi F, Fronteddu F, Del Guercio R, Arpaia MR.
    Semin Thromb Hemost; 1991 Apr; 17 Suppl 2():228-34. PubMed ID: 1948094
    [Abstract] [Full Text] [Related]

  • 4. Effects of oral and intravenous defibrotide on blood viscosity in patients with peripheral obliterative arterial disease.
    Belfiglio A, Traietti P, Bologna E, Salvo G.
    Clin Ther; 1989 Apr; 11(4):479-84. PubMed ID: 2776165
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Clinical experience in patients with chronic peripheral obliterating arteriopathy: defibrotide versus definite molecular weight heparan sulfate (MW 7500-15000 dalton)].
    Michelini S, Micci A, Failla A, Grechi G, Iantaffi A.
    Minerva Cardioangiol; 1996 Apr; 44(1-2):33-7. PubMed ID: 8767620
    [Abstract] [Full Text] [Related]

  • 7. Defibrotide and peripheral obliterative arterial disease: preliminary data.
    Arosio E, Pancera P, Zannoni M, Arcaro G, Priante F, Lechi A.
    Int J Clin Pharmacol Ther Toxicol; 1989 Nov; 27(11):526-9. PubMed ID: 2533180
    [Abstract] [Full Text] [Related]

  • 8. Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease.
    Strano A, Hoppensteadt D, Walenga JM, Fareed J, Sabbá C, Berardi E, Allegra C, Carlizza A, Binaghi F, Fronteddu F, Del Guercio R, Del Guercio M, Pinto A, Alletto G, Nazzari M, Ferrari PA.
    Semin Thromb Hemost; 1996 Nov; 22 Suppl 1():35-40. PubMed ID: 8807727
    [Abstract] [Full Text] [Related]

  • 9. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
    Arosio E, Sardina M, Prior M, De Marchi S, Zannoni M, Bianchini C.
    Eur Rev Med Pharmacol Sci; 1998 Nov; 2(2):53-9. PubMed ID: 10229559
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of tissue plasminogen activator inhibitor by defibrotide in atherosclerotic patients.
    Violi F, Ferro D, Alessandri C, Quintarelli C, Saliola M, Balsano F.
    Semin Thromb Hemost; 1989 Apr; 15(2):226-9. PubMed ID: 2501872
    [Abstract] [Full Text] [Related]

  • 11. Fibrinolytic effects of defibrotide in atherosclerotic patients.
    Patrassi GM, Sartori MT, Viero ML, Scapinello MP, Boeri G, Girolami A.
    Semin Thromb Hemost; 1991 Apr; 17 Suppl 1():101-5. PubMed ID: 2068562
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.
    Echart CL, Graziadio B, Somaini S, Ferro LI, Richardson PG, Fareed J, Iacobelli M.
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):627-34. PubMed ID: 19809307
    [Abstract] [Full Text] [Related]

  • 14. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease.
    Allegra C, Antignani PL, Schachter I, Koverech A, Messano M, Virmani A.
    Ann Vasc Surg; 2008 Dec; 22(4):552-8. PubMed ID: 18502605
    [Abstract] [Full Text] [Related]

  • 15. [Effect of a transient intravenous infusion of isozsuprin on the peripheral blood flow in patients suffering from arterial occlusive disease of the limbs. A contribution to the effect of systemically-administered vasoactive drugs].
    Ehringer H, Scheiber V.
    Wien Klin Wochenschr; 1972 Dec 15; 24(50):801-8. PubMed ID: 4642105
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Treatment of chronic obliterative arteriopathy of the legs in the second Fontaine's stage. Personal experience with a buflomedil-pentoxifylline-defibrotide combination].
    Marci M, Albiani B, Ricci M, Russo F.
    Clin Ter; 1995 Mar 15; 146(3):211-4. PubMed ID: 7789083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.